Editorial
Type 2 Diabetes: The End of Clinical Inertia
Abstract
Type 2 diabetes has reached epidemic proportions in the United States and spawned a public health crisis which has placed enormous medical and socioeconomic burdens on the healthcare system.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Campos C. Treating the whole patient for optimal management of type 2 diabetes: consideration for insulin therapy. South Med J 2007;100:804–811.2. Heine RJ, Diamant M, Mbanya JC, et al. Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? BMJ 2006;333:1200–1204.
3. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care2006;29:1963–1972.
4. Leahy JL. What is the role for insulin therapy in type 2 diabetes? Current Opinion in Endocrinology & Diabetes 2003;10:99–103.
5. Nathan DM. Thiazolidinediones for initial treatment of type 2 diabetes? N Engl J Med 2006;355:2477–2480.
6. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy.Lancet 2005;365:1333–1346.
7. Calles-Escandon J, Garcia-Rubi E, Mirza S, et al. Type 2 diabetes: one disease, multiple cardiovascular risk factors. Coron Artery Dis 1999;10:23–30.
